目的：探讨安罗替尼维持治疗应用非小细胞肺癌的临床效果及安全性研究。方法：选取2016年12月~2018年6月在我院治疗的64例非小细胞肺癌患者为研究对象，随机分为对照组32例和观察组32例，对照组患者定期复查，观察组患者采用安罗替尼维持治疗，观察参与本次研究患者的疾病缓解率、疾病控制率、KPS评分、NSE水平以及皮肤系统、消化道系统不良反应的发生率。结果：观察组患者的疾病缓解率明显高于对照组的，疾病控制率明显高于对照组的（P＜0.05）；治疗前患者血清NSE、KPS评分无显著差异，治疗4周、6周后观察组患者的血清NSE改善均显著优于对照组，治疗6周后观察组患者的KPS评分与对照组相比明显改善（P＜0.05）；两组患者出现皮肤不适、心血管疾病等不良反应的发生率无统计学意义（P＞0.05）。结论：将安罗替尼维持治疗应用非小细胞肺癌患者，可提高治疗效果，且安全性高，值得在临床进行推荐。

Objective: To study the clinical effect and safety of the maintenance treatment of non-small cell lung cancer with arotinib. Methods: 64 patients with NSCLC who were treated in our hospital from December 2016 to June 2018 were randomly divided into control group (32 cases) and observation group (32 cases). The patients in the control group were reexamined regularly. The patients in the observation group were treated with arotinib maintenance therapy. The disease remission rate, disease control rate, quality of life (KPS score) and oncology related indexes were observed The level of neuron specific enolase (NSE) in serum and the incidence of adverse reactions in skin system and digestive system. Results: the disease remission rate of 62.5% in the observation group was significantly higher than that of 46.875% in the control group, and the disease control rate of 96.875% was significantly higher than that of 68.75% in the control group (P There was no significant difference between the two groups (P > 0.05). Conclusion: the application of arotinib maintenance therapy in non-small cell lung cancer patients can improve the therapeutic effect and has high safety, which is worthy of clinical recommendation.

大同市科技局重点研发（社会发展）项目，维持剂量安罗替尼治疗晚期非小细胞肺癌临床疗效观察，2020086。